OVID Stock Summary and Trading Ideas (Ovid Therapeutics | NASDAQ:OVID)

Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.

Ovid Therapeutics trades on the NASDAQ stock market under the symbol OVID.

As of April 2, 2026, OVID stock price climbed to $2.20 with 1,341,536 million shares trading.

OVID has a beta of 1.88, meaning it tends to be more sensitive to market movements. OVID has a correlation of 0.08 to the broad based SPY ETF.

OVID has a market cap of $332.26 million. This is considered a Small Cap stock.

Last quarter Ovid Therapeutics reported $718,000 in Revenue and $.06 earnings per share. This beat revenue expectation by $584,440 and exceeded earnings estimates by $.16.

In the last 3 years, OVID traded as high as $4.14 and as low as $.24.

The top ETF exchange traded funds that OVID belongs to (by Net Assets): VTI, VXF, BSVO, PRFZ, QQQS.

OVID has outperformed the market in the last year with a return of +610.4%, while the SPY ETF gained +18.2%. In the last 3 month period, OVID beat the market returning +35.0%, while SPY returned -3.6%. However, in the most recent 2 weeks OVID has underperformed the stock market by returning -4.3%, while SPY returned -0.6%.

OVID support price is $2.02 and resistance is $2.30 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that OVID shares will trade within this expected range on the day.